Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Guilford CEO Search Ends With Appointment Of Bristol Exec

This article was originally published in The Pink Sheet Daily

Executive Summary

Bristol VP-Strategy Dean Mitchell will join Guilford Dec. 1, replacing company co-founder Craig Smith, who is retiring. Mitchell is expected to oversee a busy period for the company, which anticipates results from up to 13 late-stage clinical trials during the next 12-18 months.

You may also be interested in...



Schering-Plough's Temodar Gets Priority Review For First-Line Glioma

The supplemental application has a user fee goal date of March 2005. Phase II/III trials of the oral cytotoxic alkylating agent are ongoing for treatment of brain metastases from various cancers.

Guilford CEO Search Commences As Smith Announces Retirement Plans

Co-founder and CEO Craig Smith, MD, will retire in May 2005 unless a successor is found earlier. The company is looking for an executive with “superb credentials in commercial development, financial planning and late-stage product development” who can lead Guilford to profitability, Smith says.

Guilford Aggrastat PCI Superiority Trial Planned For 2005

The company expects to meet with FDA shortly to discuss design of a placebo-controlled superiority trial for percutaneous coronary intervention. Aggrastat sales decline beginning to slow; sales could improve in the second half of the year, Guilford says.

Related Content

Topics

UsernamePublicRestriction

Register

SC142523

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel